Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Marker Therapeutics (MRKR) Consolidated Net Income (2016 - 2025)

Historic Consolidated Net Income for Marker Therapeutics (MRKR) over the last 10 years, with Q3 2025 value amounting to -$2.0 million.

  • Marker Therapeutics' Consolidated Net Income rose 1341.01% to -$2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$14.4 million, marking a year-over-year decrease of 10650.12%. This contributed to the annual value of -$10.7 million for FY2024, which is 28473.42% down from last year.
  • Marker Therapeutics' Consolidated Net Income amounted to -$2.0 million in Q3 2025, which was up 1341.01% from -$4.1 million recorded in Q2 2025.
  • Over the past 5 years, Marker Therapeutics' Consolidated Net Income peaked at $6.6 million during Q2 2023, and registered a low of -$9.8 million during Q1 2022.
  • Over the past 4 years, Marker Therapeutics' median Consolidated Net Income value was -$2.3 million (recorded in 2024), while the average stood at -$2.2 million.
  • Its Consolidated Net Income has fluctuated over the past 5 years, first skyrocketed by 26489.77% in 2023, then crashed by 591800.31% in 2024.
  • Marker Therapeutics' Consolidated Net Income (Quarter) stood at -$813062.0 in 2022, then skyrocketed by 92.26% to -$62939.0 in 2023, then tumbled by 5918.0% to -$3.8 million in 2024, then skyrocketed by 47.23% to -$2.0 million in 2025.
  • Its last three reported values are -$2.0 million in Q3 2025, -$4.1 million for Q2 2025, and -$4.4 million during Q1 2025.